100 Recruiting Studies Using Rituximab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Rituximab
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
π The University of Arizona Cancer Center - North Campus /ID# 242219 β Tucson, Arizona
Non-Hodgkin Lymphoma
View Study & Checklist βDelayed Tolerance Through Mixed Chimerism
π Massachusetts General Hospital β Boston, Massachusetts
Kidney Failure
View Study & Checklist βStudy of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
π Johns Hopkins β Baltimore, Maryland
Immune-related Adverse Events
View Study & Checklist βA Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
π City of Hope Cancer Center β Duarte, California
Non-Hodgkin Lymphoma
View Study & Checklist βResponse-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
π National Institutes of Health Clinical Center β Bethesda, Maryland
Follicular Lymphoma
View Study & Checklist βA Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
π City of Hope Comprehensive Cancer Center β Duarte, California
Relapsed or Refractory Follicular Lymphoma
View Study & Checklist βParsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
π Mayo Clinic in Arizona β Scottsdale, Arizona
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
View Study & Checklist βA Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients
π Memorial Sloan Kettering Cancer Center β New York, New York
Lymphoma
View Study & Checklist βTafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
π MorphoSys Research Site β Daphne, Alabama
Diffuse Large B-cell Lymphoma
View Study & Checklist βA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
π University of Arizona Cancer Center - North Campus /ID# 227463 β Tucson, Arizona
Diffuse Large B-Cell Lymphoma
View Study & Checklist βA Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
π Southern Cancer Center β Mobile, Alabama
Relapsed/Refractory Follicular Lymphoma
View Study & Checklist βA Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
π Anchorage Associates in Radiation Medicine β Anchorage, Alaska
Liver Lymphoma
View Study & Checklist βCombination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Acute Lymphoblastic Leukemia
View Study & Checklist βALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
π M D Anderson Cancer Center β Houston, Texas
Aggressive B-Cell Non-Hodgkin Lymphoma
View Study & Checklist βTesting the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Diffuse Large B-Cell Lymphoma
View Study & Checklist βRituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
π Childrens Hospital of Orange County β Orange, California
Type 1 Diabetes Mellitus
View Study & Checklist βA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
π Research Site β Tucson, Arizona
Diffuse Large B-Cell Lymphoma
View Study & Checklist βPhase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
π National Institutes of Health Clinical Center β Bethesda, Maryland
Primary Central Nervous System Lymphoma
View Study & Checklist βComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy
π Memorial Sloan Kettering Basking Ridge β Basking Ridge, New Jersey
Non Hodgkin Lymphoma (NHL)
View Study & Checklist βA Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
π Novartis Investigative Site β Camperdown, New South Wales
Follicular Lymphoma (FL)
View Study & Checklist βChemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
π Fred Hutch/University of Washington Cancer Consortium β Seattle, Washington
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
View Study & Checklist βA Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
π James P. Wilmot Cancer Institute, University of Rochester Medical Center β Rochester, New York
Diffuse Large B-Cell Lymphoma
View Study & Checklist βZanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
π Cleveland Clinic β Cleveland, Ohio
Diffuse Large B-Cell Lymphoma
View Study & Checklist βNovel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
π Arthur J.E. Child Comprehensive Cancer Centre β Calgary, Alberta
Lymphoma
View Study & Checklist βA Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
π Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers β Chandler, Arizona
Relapsed/Refractory Diffuse Large B-cell Lymphoma
View Study & Checklist βGATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
π Mayo Clinic in Rochester β Rochester, Minnesota
Mantle Cell Lymphoma
View Study & Checklist βRituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Mantle Cell Lymphoma
View Study & Checklist βRituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
π Alaska Breast Care and Surgery LLC β Anchorage, Alaska
Lymphoma
View Study & Checklist βA Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
π City of Hope Cancer Center (Data collection only) β Duarte, California
Marginal Zone Lymphoma
View Study & Checklist βA Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
π University of Alabama at Birmingham School of Medicine β Birmingham, Alabama
B-cell Non-Hodgkin Lymphoma
View Study & Checklist βA Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
π Research Site β Chandler, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist βTazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
π Huntsman Cancer Institute at University of Uta β Salt Lake City, Utah
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
View Study & Checklist βRituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
π Alaska Breast Care and Surgery LLC β Anchorage, Alaska
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
View Study & Checklist βIbrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
π M D Anderson Cancer Center β Houston, Texas
Prolymphocytic Leukemia
View Study & Checklist βRenal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
π Massachusetts General Hospital β Boston, Massachusetts
Renal Failure
View Study & Checklist βA Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
π Beth Isreal Deaconess Medical Center β Boston, Massachusetts
Chronic Lymphocytic Leukemia
View Study & Checklist βCombination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
π M D Anderson Cancer Center β Houston, Texas
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
View Study & Checklist βA Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
π City of Hope National Medical Center /ID# 273338 β Duarte, California
Diffuse Large B-Cell Lymphoma
View Study & Checklist βACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
π Massachusetts General Hospital β Boston, Massachusetts
IgM MGUS
View Study & Checklist βIxazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
π Fred Hutch/University of Washington Cancer Consortium β Seattle, Washington
Chronic Lymphocytic Leukemia
View Study & Checklist βA Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
π Local Institution - 0152 β Birmingham, Alabama
Lymphoma, Follicular
View Study & Checklist βNivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
π Ohio State University Comprehensive Cancer Center β Columbus, Ohio
Aggressive Non-Hodgkin Lymphoma
View Study & Checklist βCART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
π University of Pennsylvania β Philadelphia, Pennsylvania
Glioblastoma
View Study & Checklist βStudy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
π City of Hope (City of Hope National Medical Center, City of Hope Medical Center) β Duarte, California
Relapsed/Refractory Follicular Lymphoma
View Study & Checklist βA Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
π University of Rochester β Rochester, New York
DLBCL
View Study & Checklist βZanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
π M D Anderson Cancer Center β Houston, Texas
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
View Study & Checklist βA Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
π John Muir Health Clinical Research Center β Concord, California
Follicular Lymphoma
View Study & Checklist βMoxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
π National Institutes of Health Clinical Center β Bethesda, Maryland
Hairy Cell Leukemia
View Study & Checklist βSafety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
π University of Alabama at Birmingham β Birmingham, Alabama
Diffuse Large B-Cell Lymphoma
View Study & Checklist βIbrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
π M D Anderson Cancer Center β Houston, Texas
Mantle Cell Lymphoma
View Study & Checklist βStudy of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
π Southern Cancer Center, P.C. β Daphne, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist βAcalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
π Weill Cornell Medicine β New York, New York
Mantle Cell Lymphoma
View Study & Checklist βVenetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
π Washington University School of Medicine, Siteman Cancer Center β St Louis, Missouri
Diffuse Large B-cell-lymphoma
View Study & Checklist βStudy to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
π University of Alabama Hospital β Birmingham, Alabama
High-risk Large B-cell Lymphoma (LBCL)
View Study & Checklist βSafe Accelerated Venetoclax Escalation in CLL
π Dana-Farber Cancer Institute β Boston, Massachusetts
Chronic Lymphocytic Leukemia
View Study & Checklist βTesting CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
π Banner University Medical Center - Tucson β Tucson, Arizona
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
View Study & Checklist βA Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
π M D Anderson Cancer Center β Houston, Texas
Lymphoma
View Study & Checklist βRituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
π Emory University Hospital/Winship Cancer Institute β Atlanta, Georgia
Cutaneous Melanoma, Stage III
View Study & Checklist βRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
π Ohio State University Medical Center β Columbus, Ohio
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
View Study & Checklist βComparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
B Acute Lymphoblastic Leukemia
View Study & Checklist βVorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
π Providence Hospital β Mobile, Alabama
Ann Arbor Stage II Non-Hodgkin Lymphoma
View Study & Checklist βIbrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
π M D Anderson Cancer Center β Houston, Texas
Blastoid Variant Mantle Cell Lymphoma
View Study & Checklist βLow-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
π M D Anderson Cancer Center β Houston, Texas
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
View Study & Checklist βAn Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
π Alaska Oncology & Hematology, LLC β Anchorage, Alaska
Large B-Cell Lymphoma
View Study & Checklist βAcalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
π M D Anderson Cancer Center β Houston, Texas
Ann Arbor Stage III Grade 1 Follicular Lymphoma
View Study & Checklist βBIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)
π Cedars-Sinai Medical Center- Site Number : 8400100 β Los Angeles, California
Transplant Rejection
View Study & Checklist βLoncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
π University of Texas Southwestern β Dallas, Texas
B-cell Lymphoma
View Study & Checklist βBortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
π University of Texas MD Anderson Cancer Center β Houston, Texas
Waldenstrom's Macroglobulinemia
View Study & Checklist βLenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
π MedStar Georgetown University Hospital β Washington D.C., District of Columbia
Recurrent Chronic Lymphocytic Leukemia
View Study & Checklist βStudy of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
π Research Site β Tucson, Arizona
Non Hodgkin Lymphoma
View Study & Checklist βRituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
π M D Anderson Cancer Center β Houston, Texas
Diffuse Large B-Cell Lymphoma
View Study & Checklist βLTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
π University of Alabama at Birmingham β Birmingham, Alabama
Central Nervous System Lymphoma
View Study & Checklist βA Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment NaΓ―ve Mantle Cell Lymphoma
π Research Site β Hackensack, New Jersey
Mantle Cell Lymphoma (MCL)
View Study & Checklist βPersonalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma
π Dana Farber Cancer Institute β Boston, Massachusetts
Follicular Lymphoma
View Study & Checklist βPolatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
π Fred Hutch/University of Washington Cancer Consortium β Seattle, Washington
Aggressive Non-Hodgkin Lymphoma
View Study & Checklist βRituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
π M D Anderson Cancer Center β Houston, Texas
Recurrent Diffuse Large B-Cell Lymphoma
View Study & Checklist βRituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Stage I Chronic Lymphocytic Leukemia
View Study & Checklist βIntrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma
π UC Health β Cincinnati, Ohio
Non Hodgkin Lymphoma
View Study & Checklist βA Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
π University of Miami Sylvester Comprehensive Cancer Center β Coral Gables, Florida
Chronic Lymphocytic Leukemia
View Study & Checklist βA Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
π Ironwood Physicians, Ironwood Cancer and Research Centers β Chandler, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist βPhase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
π BCCA - Vancouver β Vancouver, British Columbia
Lymphoma, B-Cell
View Study & Checklist βA Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
π Hospital Aleman β Ciudad Autonoma de Buenos Aires, Buenos Aires
B-Cell Non-Hodgkin Lymphoma (B-NHL)
View Study & Checklist βPolatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
π City of Hope Medical Center β Duarte, California
Diffuse Large B-Cell Lymphoma Unclassifiable
View Study & Checklist βStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
π UCSF Fresno /ID# 264712 β Fresno, California
Follicular Lymphoma (FL)
View Study & Checklist βDose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
π The Cancer Center at Hackensack University Medical Center β Hackensack, New Jersey
Mantle Cell Lymphoma
View Study & Checklist βA Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
π Boca Raton Clinical Research (BRCR) Global β Plantation, Florida
Follicular Lymphoma (FL)
View Study & Checklist βProvision of TCRΞ³Ξ΄ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in NaΓ―ve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
π St. Jude Children's Research Hospital β Memphis, Tennessee
Acute Lymphoblastic Leukemia (ALL)
View Study & Checklist βTafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
π Fred Hutch/University of Washington Cancer Consortium β Seattle, Washington
Diffuse Large B-Cell Lymphoma
View Study & Checklist βA Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
π Chao Family Comprehensive Cancer Center β Orange, California
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
View Study & Checklist βRandomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
π National Institutes of Health Clinical Center β Bethesda, Maryland
Hairy Cell Leukemia
View Study & Checklist βA Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
π California Research Institute β Los Angeles, California
Chronic Lymphocytic Leukemia
View Study & Checklist βNivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
π Children's Hospital of Alabama β Birmingham, Alabama
Primary Mediastinal Large B-Cell Lymphoma
View Study & Checklist βIbrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Anemia
View Study & Checklist βA Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
π George Washington Cancer Center β Washington D.C., District of Columbia
Marginal Zone Lymphoma
View Study & Checklist βA Study of Enasidenib in People With T-Cell Lymphoma
π Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) β Basking Ridge, New Jersey
T-cell Lymphoma
View Study & Checklist βA Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
π City of Hope Comprehensive Cancer Center β Duarte, California
Lymphoma
View Study & Checklist βAlisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
π Laura and Isaac Perlmutter Cancer Center at NYU Langone β New York, New York
Recurrent B-Cell Non-Hodgkin Lymphoma
View Study & Checklist βA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
π Highlands Oncology Group ( Site 5205) β Springdale, Arkansas
Chronic Lymphocytic Leukemia
View Study & Checklist βA Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
π Augusta University β Augusta, Georgia
Chronic Lymphocytic Leukemia
View Study & Checklist βAcalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
π M D Anderson Cancer Center β Houston, Texas
Mantle Cell Lymphoma
View Study & Checklist β